News
FDA Approves Blood-Based Test as Companion Diagnostic for Multiple Cancer Drugs
Using a blood sample, the test is able to analyze more than 300 cancer-associated genes for alterations.
Your search for non small cell lung cancer returned 16 results
News
FDA Approves Imfinzi for Extensive-Stage Small Cell Lung Cancer
The approval was based on data from the CASPIAN study, an active-controlled, open-label trial that investigated the combination of durvalumab plus chemotherapy vs chemotherapy alone.
News
Keytruda Approved for BCG-Unresponsive, High-Risk Non-Muscle Invasive Bladder Cancer
The Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab; Merck) for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.
News
Antibiotic Use May Impact PFS, Overall Survival in Lung Cancer Patients Treated With Pembrolizumab
In patients with naïve advanced non-small cell lung cancer (NSCLC) and high PD-LI expression who are treated with pembrolizumab, the use of intravenous (IV) antibiotics may negatively impact progression free survival (PFS) and overall survival, according to research presented at the IASLC 2019 World Conference on Lung Cancer. To evaluate the effect of antibiotics on…
News
Keytruda Wins Approval for Advanced Esophageal Cancer
The FDA approved Keytruda for the treatment of patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus whose tumors express PD-L1 (CPS ≥10) as determined by an FDA-approved test
News
Keytruda Approved to Treat Metastatic Small Cell Lung Cancer
The approval was based on data from 83 patients with SCLC who were enrolled in either the KEYNOTE-028 or KEYNOTE-158 trials.
News
Cyramza Approved to Treat Hepatocellular Carcinoma
The FDA has approved Cyramza (ramucirumab; Lilly) for use as a single agent in the treatment of patients with hepatocellular carcinoma (HCC) who have an alpha fetoprotein (AFP) of ≥400ng/mL and have been treated with sorafenib.
Drugs in the Pipeline
Poziotinib Under Review for Previously Treated HER2 Exon 20 Insertion Mutation Positive NSCLC
A PDUFA target date of November 24, 2022 has been set for the application.
News
Lorbrena Approved for First-Line Treatment of ALK-Positive Metastatic NSCLC
Lorbrena is a third generation ALK tyrosine kinase inhibitor.
News
Cyramza Plus Erlotinib Approved for First-Line Metastatic NSCLC With EGFR Mutations
The FDA has approved Cyramza (ramucirumab; Lilly) in combination with erlotinib, for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.
